FDA green lights Pfizer drug for ulcerative colitis

May 30, 2018

The FDA has expanded its approval for Pfizer’s drug Xeljanz.

Currently, Xeljanz has been OK’d to treat rheumatoid and psoriatic arthritis. Now, it can be used for adult patients suffering from moderate to severe ulcerative colitis.

The company based its application for the approval on three successful controlled clinical trials that showed the drug the caused remission in about 17-18 percent of patients.

Pfizer anticipates that sales for Xeljanz could reach $2.16 billion in 2019.

Read the full Reuters report.  

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments